title: Systemic administration of human adipose-derived stem cells reverts nociceptive hypersensitivity in an experimental model of neuropathy.
abstract: Over the last decade, it has been proved that mesenchymal stem cells (MSCs) elicit anti-inflammatory effects. MSCs from adipose tissue (hASCs) differentiate into cells of the mesodermal lineage and transdifferentiate into ectodermal-origin cells. Although there are various etiologies to chronic pain, one common feature is that painful states are associated with increased inflammation. We believe in hASCs as a therapeutic tool also in pathologies involving neuroinflammation and neuronal tissue damage. We have investigated the effect of hASCs injected in a model of neuropathic pain [(mouse sciatic nerve chronic constriction injury (CCI)]. hASCs from 5 donors were characterized, and no major differences were depicted. hASCs were cryopreserved and grown on demand. About 1×10(6), 3×10(6), and 6×10(6) hASCs were intravenously injected into normal immunocompetent mice. No mouse died, and no macroscopic toxicity or behavioral changes were observed, confirming the safety of hASCs. hASCs, intravenously (i.v.) injected into C57BL/6 mice when the neuropathic pain was already established, induced a significant reduction in mechanical allodynia and a complete reversion of thermal hyperalgesia in a dose-response fashion, already 1 day after administration. Moreover, the hASCs effect can be boosted by repeated administrations, allowing a prolonged therapeutic effect. Treatment decreased the level of the CCI-induced proinflammatory cytokine interleukin (IL)-1β and activated the anti-inflammatory cytokine IL-10 in the lesioned nerve. hASCs treatment also restored normal inducible nitric oxide synthase expression in the spinal cord of CCI animals. Our data suggest that hASCs are worthy of further studies as an anti-inflammatory therapy in the treatment of neuropathic pain or chronic inflammatory diseases.
authors.affiliation: Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Sacerdote
authors.forename: Stefania
authors.initials: S
authors.lastname: Niada
authors.forename: Silvia
authors.initials: S
authors.lastname: Franchi
authors.forename: Elena
authors.initials: E
authors.lastname: Arrigoni
authors.forename: Alice
authors.initials: A
authors.lastname: Rossi
authors.forename: Vijay
authors.initials: V
authors.lastname: Yenagi
authors.forename: Laura
authors.initials: L
authors.lastname: de Girolamo
authors.forename: Alberto Emilio
authors.initials: AE
authors.lastname: Panerai
authors.forename: Anna Teresa
authors.initials: AT
authors.lastname: Brini
mesh_terms: D000273:Adipose Tissue / Q000166:cytology*; D000328:Adult; D053687:Adult Stem Cells / Q000166:cytology* / Q000637:transplantation; D000818:Animals; D015153:Blotting, Western; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D006930:Hyperalgesia / Q000209:etiology / Q000378:metabolism / Q000601:surgery; D018836:Inflammation Mediators / Q000378:metabolism; D007275:Injections, Intravenous; D016753:Interleukin-10 / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008875:Middle Aged; D009437:Neuralgia / Q000209:etiology / Q000378:metabolism / Q000601:surgery*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D020426:Sciatic Neuropathy / Q000150:complications / Q000378:metabolism; D033581:Stem Cell Transplantation / Q000379:methods; D013997:Time Factors
chemical_list: D018836:Inflammation Mediators; D053583:Interleukin-1beta; D016753:Interleukin-10; D052247:Nitric Oxide Synthase Type II